In this issue:
2021 consensus recommendations on the use of MRI in MS
Risk of persistent disability in patients with paediatric-onset MS
PML in a patient with progressive MS treated with ocrelizumab
Medical diagnoses preceding the first diagnosis of MS
Natalizumab, fingolimod, and dimethyl fumarate and pregnancy-related relapse and disability in MS
Retinal layer thinning predicts treatment failure in relapsing MS
HLA genotypes and environmental interactions in MS aetiology
Gut microbiome in progressive MS
Serum lactate as a biomarker in MS
FAERS AE profile differences between rituximab and ocrelizumab
Please login below to download this issue (PDF)